Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: 100mg SPN-812, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 48 Months to 69 Months
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 54
States / cities: Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more

Conditions: Traumatic Brain Injury
Interventions: Armodafinil, Placebo; Drug · Other
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 68
States / cities: Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more

Conditions: ADHD, Weight Loss
Interventions: Adaptive Working Memory Training, Non-adaptive cognitive training; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Healthy Volunteers
Interventions: AZD8108, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: HNC042 single dose, Placebo single dose, HNC042 multiple ascending doses, Placebo multiple ascending doses; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Biliary Cholangitis
Interventions: K-808 (Dose A), K-808 (Dose B), Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more

Conditions: Herpes Genitalis
Interventions: Valaciclovir, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Bilateral Nasal Polyposis
Interventions: OPN-375; Drug
Lead sponsor: Optinose US Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 22
States / cities: Gilbert, Arizona • Bakersfield, California • Fresno, California + 18 more

Conditions: Hypercholesteremia
Interventions: Rosuvastatin calcium; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 45 Years to 70 Years
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 20
States / cities: Alhambra, California • La Jolla, California • Los Angeles, California + 17 more

Conditions: Acne Vulgaris
Interventions: Tretinoin cream, 0.05%, RETIN-A® (tretinoin) cream, 0.05%, Vehicle of the test product; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Crohn's Disease
Interventions: CC-5013; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 5
States / cities: Tucson, Arizona • Anaheim, California • Washington D.C., District of Columbia + 2 more

Conditions: Diabetic Polyneuropathy
Interventions: Eptinezumab, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Insomnia
Interventions: Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 12
States / cities: Tucson, Arizona • Little Rock, Arkansas • Brandon, Florida + 8 more

Conditions: Opioid Dependence, Chronic Pain
Interventions: Ketamine, Placebo Comparator; Drug
Lead sponsor: Jacques E. Chelly; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: Acidform 5 g, Placebo 4 g, Acidform 4 g, Acidform 3 g; Drug
Lead sponsor: Evofem Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Cleveland, Ohio

Conditions: Acne Vulgaris
Interventions: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 541 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 22
States / cities: Mobile, Alabama • Kingman, Arizona • Encino, California + 18 more

Conditions: Healthy
Interventions: 1 mg, 5 mg, 10 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Culver City, California • Glendale, California

Conditions: Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 96
States / cities: Mobile, Alabama • Mesa, Arizona • Oro Valley, Arizona + 93 more

Conditions: Nicotine Dependence
Interventions: Varenicline, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: Benralizumab, Placebo to Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Birmingham, Alabama • Newport Beach, California • Northridge, California + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK256073 1mg, GSK256073 5mg, GSK256073 10mg, GSK256073 25mg, Placebo, Sitagliptin 100mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Anniston, Alabama • Miami, Florida • Miramar, Florida

Conditions: Renal Insufficiency, Chronic, Hypertension
Interventions: Chlorthalidone, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Heart Failure
Interventions: LCZ696, Valsartan, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 11
States / cities: Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more

Conditions: Enterocolitis Clostridium Difficile Recurrent
Interventions: RBX2660 (microbiota suspension), Placebo; Biological · Other
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 19
States / cities: Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 15 more

Search by objective public record fields.

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

Obesity Treatment Enhanced With Working Memory Training

AZD8108 SAD/MAD in Healthy Volunteers

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery

Duration of Effect of Acidform Gel on Vaginal pH

Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol

Effects of Varenicline on Smoking Reminders

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin

Chlorthalidone in Chronic Kidney Disease

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection